Exelixis Inc
(NAS:EXEL)
$
36.115
0.265 (0.74%)
Market Cap: 10.31 Bil
Enterprise Value: 9.21 Bil
PE Ratio: 23.15
PB Ratio: 4.54
GF Score: 91/100 
Exelixis Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021 / 07:05PM GMT
Release Date Price:
$23.6
(-3.04%)
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research
Hi. My name is Kennen MacKay. Iâm one of the biotechnology analysts here at RBC, and it's my great pleasure to kick off our next session with Exelixis. From Exelixis, we have Mike Morrissey, the President and Chief Executive Officer. Mike, thank you so much for joining us here.
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
Kennen, how are you doing, man? Good to see you.
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research
I'm doing well. I'm actually right across the South Bay from you now, and it's a treat to be out in the bay area.
Michael M. Morrissey;Kennen B. MacKay
Exelixis, Inc. - CEO, President & Director;RBC Capital Markets, Research Division - MD & Co-Head of US
Yes. I heard you moved. So looking forward to doing this live next year, right?
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers